Acute Porphyria Drugs

Monograph

P01AX06 - Atovaquone
Propably not porphyrinogenic
PNP

Rationale
Not significantly metabolised.
Chemical description
Antibiotic used in acute treatment of Pneumocystis carnii- pneumonia (PCP) of moderate severity in patients that cannot tolerate trimethoprim - sulfamethoxazol. Admiistered as oral susspsion 1500 mg daily for 21 days Highly lipophilic substance with restricted bioavailability. Clinically efficient plasma concentration is 15 mg/ml. Excreted in unchanged form in stool. South African list: No data/avoid
IPNet drug reports
Uneventful use reported in 4 patients with acute porphyria.
Similar drugs
Explore alternative drugs in similar therapeutic classes P01A / P01AX or go back.
References
Tradenames

Atovaquon · Wellvone Wellvone Atovacuona · Wellvone Wellvone Atovaquone · Wellvone Atovaquone Wellvone Wellvone Wellvone Atovaquone · Mepron · Wellvone Atovacuona Atovaquone
In cooperation with IpNet
© NAPOS 2025
An unhandled error has occurred. Reload 🗙